MDT - Medtronic plc

NYSE - NYSE Delayed Price. Currency in USD
97.29
+0.74 (+0.77%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close96.55
Open95.63
Bid95.72 x 3000
Ask99.12 x 800
Day's range95.33 - 97.40
52-week range76.41 - 100.15
Volume5,105,542
Avg. volume4,765,856
Market cap131.391B
Beta (3Y Monthly)0.62
PE ratio (TTM)41.95
EPS (TTM)2.32
Earnings date20 Nov 2018
Forward dividend & yield2.00 (2.11%)
Ex-dividend date2018-09-27
1y target est103.90
Trade prices are not sourced from all markets
  • Investing.comyesterday

    Medtronic Rises 3%

    Investing.com - Medtronic (NYSE:MDT) rose by 3.03% to trade at $96.66 by 14:29 (18:29 GMT) on Tuesday on the NYSE exchange.

  • What to Expect from Medtronic’s Diabetes Segment
    Market Realist2 days ago

    What to Expect from Medtronic’s Diabetes Segment

    In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depositary share (or $29.25 per ordinary share), which amounts to a total of $1.64 billion (or $1.34 billion). Both companies’ boards of directors unanimously approved the transaction.

  • The Latest from Medtronic’s Cardiac & Vascular Therapies Group
    Market Realist2 days ago

    The Latest from Medtronic’s Cardiac & Vascular Therapies Group

    Medtronic’s (MDT) Cardiac & Vascular Group consists of cardiac rhythm and heart failure, coronary and structural heart, aortic, and peripheral and venous products. Medtronic’s Cardiac and Vascular Group generated revenues of $2.8 billion in the first quarter of fiscal 2019 compared to $2.6 billion in the first quarter of fiscal 2018, a ~6% year-over-year (or YoY) increase.

  • CNBC2 days ago

    Cramer's lightning round: Cisco's stock is a buy ahead of the company's earnings report

    Jim Cramer zips through his take on callers' favorite stocks, including a technology hardware giant in the throes of marketwide weakness.

  • Key Updates on Medtronic’s Restorative Therapies Group
    Market Realist3 days ago

    Key Updates on Medtronic’s Restorative Therapies Group

    Medtronic’s (MDT) Restorative Therapies Group consists of spine, brain, specialty, and pain therapies. The segment generated net revenues of $1.9 billion in the first quarter of fiscal 2019 compared to $1.8 billion in the first quarter of fiscal 2018, reflecting an ~8% YoY increase.

  • How Is Medtronic Positioned in October?
    Market Realist3 days ago

    How Is Medtronic Positioned in October?

    In the first quarter of fiscal 2019, Medtronic generated net revenues of $7.4 billion, a ~0.1% year-over-year (or YoY) decline. Wall Street analysts estimate that Medtronic will generate revenues of $7.3 billion in the second quarter of fiscal 2019.

  • What Analysts Recommend for Medtronic
    Market Realist3 days ago

    What Analysts Recommend for Medtronic

    How Is Medtronic Positioned in October? On October 12, Medtronic stock closed at $94.69, which is a ~1.7% rise from its prior-day close of $93.11 on October 11 and a ~24% rise from its 52-week low of $76.41. Medtronic hit its 52-week high of $100.15 on September 26, 2018.

  • Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results
    Market Realist6 days ago

    Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results

    Edwards Lifesciences (EW) is a leading transcatheter heart valve manufacturer in the United States. The company is set to release its third-quarter earnings results after the market closes on October 23. In this article, we’ll look at analysts’ recommendations and target prices for EW ahead of its third-quarter earnings release. According to an October 12 Reuters survey, which included 21 analysts covering EW stock, 62% of analysts (or 13) have recommended “buys” or “strong buys” on Edwards Lifesciences.

  • Could JNJ’s Medical Device Business Report Strong Growth in Q3?
    Market Realist6 days ago

    Could JNJ’s Medical Device Business Report Strong Growth in Q3?

    Johnson & Johnson’s (JNJ) Medical Device business has posted steadily improving performance in recent quarters. Since then, Johnson & Johnson has efficiently implemented a restructuring plan for its Medical Device business, which resulted in significant growth in the segment’s performance. In the second quarter, Johnson & Johnson’s Medical Device business reported sales of ~$7.0 billion, which contributed 33.5% to the company’s total sales of $20.8 billion.

  • JNJ’s Consumer Business Expected to Be Driven by Innovation
    Market Realist7 days ago

    JNJ’s Consumer Business Expected to Be Driven by Innovation

    Johnson & Johnson (JNJ) is scheduled to report its third-quarter earnings on October 16. The company’s second-quarter growth in its Consumer business was below expectations. However, it expects to accelerate the segment’s growth in the second half of the year, driven mainly by the introduction of new products. The company’s other two business segments are Pharmaceuticals and Medical Devices. Johnson & Johnson’s Consumer business consists of a range of products across its baby care, oral care, women’s health, beauty, wound care, and over-the-counter franchises.

  • ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade
    Market Realist7 days ago

    ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade

    On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close. On the day, Morgan Stanley raised its target price on ABT stock from $70 to $80. However, the stock price dropped as the broader market sell-off pulled down ABT stock prices along with a large number of other healthcare stocks. The SPDR S&P 500 ETF (SPY) was down ~3.2% on October 10.

  • Analysts Raise Target Prices on ABT ahead of Q3 Earnings
    Market Realist7 days ago

    Analysts Raise Target Prices on ABT ahead of Q3 Earnings

    Abbott Laboratories (ABT) is slated to announce its Q3 earnings results on October 17. Let’s look at Wall Street analysts’ recommendations for ABT stock ahead of its earnings release.

  • How Intuitive’s Bottom Line Is Expected to Look in Q3 2018
    Market Realist8 days ago

    How Intuitive’s Bottom Line Is Expected to Look in Q3 2018

    Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% from $227.5 million in the third quarter of 2017 to $265.76 million in the third quarter of 2018. In the third quarter, Intuitive Surgical is expected to incur selling, general, and administrative expenses of $207.11 million compared to $204.8 million in the third quarter of 2017, reflecting a potential increase of 1.13%. Intuitive Surgical is expected to report net income of $258.28 million in the third quarter compared to net income of $297.5 million in the third quarter of 2017, indicating a contraction of 13.18% in the company’s net margins.

  • Why Most Analysts Are Bullish on Intuitive Surgical in October
    Market Realist8 days ago

    Why Most Analysts Are Bullish on Intuitive Surgical in October

    Eleven of the 18 analysts covering Intuitive Surgical (ISRG) in October have given the stock “buy” or higher ratings. Six analysts have given it “hold” ratings, and one has given it a “sell” rating.

  • Why Mazor Robotics Ltd. Stock Popped 20.6% in September
    Motley Fool8 days ago

    Why Mazor Robotics Ltd. Stock Popped 20.6% in September

    The robotic-assisted spinal surgery specialist is being acquired by Medtronic. Here's what investors need to know.

  • The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom
    Zacks9 days ago

    The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom

    The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom

  • Wearable Medical Device Boom Puts These 3 Stocks in Focus
    Zacks10 days ago

    Wearable Medical Device Boom Puts These 3 Stocks in Focus

    Americans depend on wearable medical devices for fitness tracking, blood pressure maintenance, self-glucose monitoring and more. Here, we discuss major companies that are raking in huge profits.

  • How Important Are Boston Scientific’s Valuation Multiples?
    Market Realist12 days ago

    How Important Are Boston Scientific’s Valuation Multiples?

    On October 4, Boston Scientific (BSX) was trading at a forward PE ratio of 24.7x compared to the industry average of 22.9x. Let’s look at another key valuation multiple, the EV-to-EBITDA ratio, which is a capital structure–neutral valuation metric. Boston Scientific’s forward EV-to-EBITDA multiple is 19.4x, which is higher than the industry average of 17.3x.

  • Analysts Still Bullish on Boston Scientific Stock in October
    Market Realist13 days ago

    Analysts Still Bullish on Boston Scientific Stock in October

    Boston Scientific (BSX) stock traded at its 52-week high on October 2. It has seen tremendous growth momentum over the past year on the back of strong product launches, approvals, and acquisitions.

  • What Triggered a 52-Week High for Boston Scientific in October?
    Market Realist13 days ago

    What Triggered a 52-Week High for Boston Scientific in October?

    Boston Scientific Has Massive Bull Run: Is There More Upside? On October 3, Boston Scientific (BSX) stock closed at $38.61, a decline of ~1.1% compared to $39.04 on October 2. It hit a 52-week high of $39.44 during the day on October 2 when Morgan Stanely raised its target price.

  • ABT Stock Registered a 52-Week High in October
    Market Realist13 days ago

    ABT Stock Registered a 52-Week High in October

    On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close. The stock registered a 52-week high of $74.15 on October 1. Throughout the week, it’s fallen ~1.6%.

  • GlobeNewswire13 days ago

    Detailed Research: Economic Perspectives on Newfield Exploration, Spirit Aerosystems, OSI, News Corporation, Coca-Cola European Partners, and Medtronic — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Oct. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • US Diabetes Market Gaining Momentum: 3 Stocks in Focus
    Zacks14 days ago

    US Diabetes Market Gaining Momentum: 3 Stocks in Focus

    A rising geriatric population and lifestyle disorders are expanding the U.S. diabetic population.

  • Is Intuitive Surgical's Momentum Unstoppable?
    Motley Fool16 days ago

    Is Intuitive Surgical's Momentum Unstoppable?

    Intuitive stock is at an all-time high. But can it go even higher?

  • How GlaxoSmithKline’s Pharmaceutical Business Performed
    Market Realist17 days ago

    How GlaxoSmithKline’s Pharmaceutical Business Performed

    GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products. During the second quarter of 2018, the Pharmaceutical segment reported a 1% increase in operating revenues to ~4.23 billion pounds.